Analyzing CRISPR Therapeutics (NASDAQ:CRSP) and Vitro Diagnostics (OTCMKTS:VODG)

Vitro Diagnostics (OTCMKTS:VODG) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings & Valuation

This table compares Vitro Diagnostics and CRISPR Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vitro Diagnostics	$1.76 million	N/A	-$5.36 million	($1.67)	-0.24
CRISPR Therapeutics	$371.21 million	12.84	-$153.61 million	($1.96)	-28.65

Vitro Diagnostics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vitro Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vitro Diagnostics and CRISPR Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vitro Diagnostics	-474.01%	-1,020.38%	-105.94%
CRISPR Therapeutics	N/A	-8.09%	-6.73%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Vitro Diagnostics and CRISPR Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vitro Diagnostics	0	0	0	0	N/A
CRISPR Therapeutics	2	6	8	0	2.38

CRISPR Therapeutics has a consensus price target of $76.29, suggesting a potential upside of 35.84%. Given CRISPR Therapeutics’ higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Vitro Diagnostics.

Insider and Institutional Ownership

69.2% of CRISPR Therapeutics shares are owned by institutional investors. 27.7% of Vitro Diagnostics shares are owned by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

CRISPR Therapeutics beats Vitro Diagnostics on 7 of the 11 factors compared between the two stocks.

About Vitro Diagnostics

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.